Active
A Phase I Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3’-Deoxy-3’-18F Fluorothymidine (18F-FLT) Imaging
Type of Sarcoma:
Ewing Sarcoma
Drug:
Trabectedin and Irinotecan
Accrual Status:
Recruiting
Overall Study Principal Investigator:
Patrick Grohar, MD, PhD
Associate Professor / Director of Translational Research
Center for Childhood Cancer Research
Children’s Hospital of Philadelphia
Associate Professor / Director of Translational Research
Center for Childhood Cancer Research
Children’s Hospital of Philadelphia